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Objectives: This analysis aimed to investigate potential differences in estimated 
survival outcomes between partitioned survival models and state transition 
(Markov) models in the common three-state model of pre-progression, post-progres-
sion, and death by using nivolumab trial data in advanced melanoma. MethOds: 
Each approach was applied separately to patient-level data from a phase 1b trial of 
nivolumab in 304 patients with previously treated advanced solid tumors (107 mela-
noma patients). All patients were included in parametric survival analyses (with a 
parameter identifying melanoma patients) to model overall survival (OS), progres-
sion free survival (PFS), and post-progression survival (PPS) to extrapolate (10 years) 
beyond maximum trial follow-up for melanoma patients specifically. Alternative 
fits to the data were compared on the basis of Akaike Information Criterion (AIC) 
and the plausibility of the long-term extrapolation. Results: The Weibull para-
metric model was judged to be the most conservative in terms of extrapolation 
and forms the basis of these results. Log-normal and log-logistic generally had 
better fit in terms of AIC, but fatter tails were less suitable for extrapolation. The 
area under the curve (AUC) for extrapolated PFS and OS was 23.5 and 41.5 months, 
respectively, suggesting 18 months of PPS using the partitioned survival approach. 
The AUC for PPS was 12.5 months, which gives an estimated OS of 36 months under 
the Markovian assumption. Relaxing this assumption to allow time dependency 
for transitioning between states with a Weibull model for PPS gives an estimated 
PPS of 17.1 months and an OS of 40.6 months. cOnclusiOns: Partitioned sur-
vival modeling and Markov modeling make intrinsically different assumptions; 
nevertheless, by relaxing the Markovian assumption and allowing time dependency, 
the two modeling forms are shown to be functionally equivalent. The selection of 
approach should be driven by what best represents the disease, treatment effect, 
and available clinical data.
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Objectives: To compare the economic results of a non-randomized study using 
propensity score (PS) methodology to adjust for confounding versus a restriction 
approach based on clinical opinion. MethOds: We used data from a published 
non-randomized study, which enrolled 195 patients (58.2%) to receive open surgi-
cal repair (OSR) and 140 patients (41.8%) to receive endovascular aneurysm repair 
(EVAR) for the treatment of abdominal aortic aneurysm. OSR patients were classi-
fied as being at low risk (LR) or high risk (HR) for post-surgical complications based 
on clinical opinion and scoring algorithms while all EVAR patients were classified 
as HR. The database included baseline characteristics, patient level 1-year cost 
and survival data. One-to-one PS matching was used within the full population 
to select a more balanced patient sub-population. Incremental cost-effectiveness 
ratios (ICERs) were assessed within the HR sub-population and the PS-matched 
sub-population. Results: The HR sub-population was composed of all 140 EVAR 
patients (100.0%) and 50 OSR patients (25.6%). EVAR was identified as the dominant 
treatment option within the HR sub-population. The PS-matched sub-population 
was composed of 77 HR EVAR patients (55.0%) and 77 OSR patients (39.5%), of which 
48 (62.3%) were OSR-LR patients and 29 (37.7%) were OSR-HR patients. Unlike results 
obtained within the HR sub-population, the ICER of EVAR was estimated at $93,608 
per life-year gained within the PS-matched sub-population. Differences in the 
results may be explained by confounding; although balance was improved within 
the PS-matched sub-population, unbalance remained on several patient charac-
teristics. cOnclusiOns: Results of this study highlight the fact that PS matching 
may not always fully adjust for confounding. Clinical opinion may be influenced by 
unmeasured confounders which may not be adjusted for by PS matching. Balance 
within patient subsets following PS matching must be evaluated when conducting 
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Objectives: Final phase III trial results of the first malaria vaccine candidate RTS,S 
have been published. Based on these results, our study aims at estimating the public 
health impact and cost-effectiveness of RTS,S implementation in infants in 42 sub-
Saharan countries. MethOds: We developed a stochastic individual-based Markov 
model, calibrated against data from the control and vaccine arms of the RTS,S 
vaccine trial, published age distribution data and case-fatality rate. The simulated 
2017 birth cohort was vaccinated at 6, 10, 14 weeks without and with a 4th dose at 
21 months of age and followed-up over 15 years. Impact of sequelae and mortality 
was accounted over lifetime. Country-specific inputs were demographics, parasite 
prevalence, access to care, and diphtheria-tetanus-pertussis third dose vaccina-
tion coverage (DTP-coverage), with RTS,S 4th dose coverage assumed at 80% DTP-
coverage. Costs for malaria outpatient visits and hospitalizations were taken from 
a study in 3 sub-Saharan countries. RTS,S price and cost of administration per dose 
dation. Results: Forty-two assessments were published. Of these, sofosbuvir 
was the focus of 29% of assessments, followed by simeprevir (26%), daclatasvir 
(12%) and ledipasvir + sofosbuvir (12%). These 33 HTAs met the criteria for fur-
ther analysis. Eleven recommendations were positive without restriction (33%); 
20 were positive with restrictions (60%) and two were negative (6%). Ledipasvir + 
sofosbuvir received the lowest proportion of positive recommendations without 
restriction (20%). Simeprevir and daclatasvir had the highest proportions, with 
41% and 41%, respectively. Sofosbuvir, the first marketed and highest priced, was 
the only drug to receive negative recommendations. Clinical benefit was recog-
nised as being an important criteria in 19 (58%) of the 33 reports. The main nega-
tive critique (reported in 11/33 cases) was lack of direct comparative evidence 
and the resulting uncertainty around cost-effectiveness. In three cases, positive 
recommendations were based on price negotiations with the manufacturer. The 
20 positive recommendations were restricted to subpopulations where the cost-
effectiveness was highest (progressed patients, with fibrosis and facing transplan-
tation). cOnclusiOns: Recently, 4 effective, but costly HCV drugs were launched. 
No clear trend was observed regarding order of market entry and HTA recommen-
dation. However, in most cases, agencies restricted access to subpopulations. Cost 
seemed to be a key decision driver: simeprevir and daclatasvir most often received 
a positive recommendation.
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Objectives: Participants in oncology randomised controlled trials (RCT) are often 
permitted to switch from their randomised treatments onto alternative treat-
ments. Intention-to-treat (ITT) assessments are prone to bias in the presence of 
switching and consequently the overall survival (OS) benefit and cost-effectiveness 
of the novel treatment may be underestimated. Regardless, decision-makers fre-
quently reject statistical analyses which adjust for treatment switching in health 
technology assessment, often due to poor justification of methodological assump-
tions. This study applies adjustment methods to an RCT comparing dabrafenib 
to dacarbazine in patients with BRAF V600E/K mutation-positive metastatic mel-
anoma, and investigates which adjustment method best fits this specific case 
study. MethOds: The adjustment methods applied included the Rank Preserving 
Structural Failure Time Model (RPSFTM), Inverse Probability of Censoring Weights 
(IPCW), and two-stage adjustment. The suitability of each method was assessed 
by investigating their assumptions and trial characteristics. Results: 37/63 
(58.7%) dacarbazine patients switched to dabrafenib (direct switching). Also, 16 
(25.4%) dacarbazine patients and 27 (14.4%) of 187 dabrafenib patients received 
other small molecule targeted treatments post-study (indirect switching). The 
ITT hazard ratio (HR) for OS was 0.81 (95% confidence intervals (CI) 0.56 - 1.16,) 
favouring dabrafenib. An RPSFTM analysis to adjust for direct switching, com-
bined with a two-stage analysis to adjust for indirect switching, appeared most 
appropriate, producing an adjusted HR of 0.68 (95% CI 0.33 - 1.63). It was not pos-
sible to robustly adjust for direct and indirect switching simultaneously using 
standalone IPCW or two-stage methods due to small patient and event numbers. 
Whilst it is not possible to perfectly test the common treatment effect assumption 
required by the RPSFTM, our investigations did not find strong evidence against 
this. cOnclusiOns: Adjusting for switching showed an increased OS effect for 
dabrafenib. Methodological assumptions must be rigorously investigated to dem-
onstrate whether and which adjustment methods are justified.
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Objectives: The standard approach to derive transition probabilities for use in 
state-transition cost-effectiveness models based on available risk functions with dif-
ferent time horizon than the model cycle length is to use an exponential distribution 
(constant event rate assumption) to derive model cycle risk. However this does not 
remove any age effect on risk, resulting in potential overestimation of cycle-specific 
risks in the case age is included as a risk factor. We present an approach for annuali-
zation of event risk predictions that ensures the correct risk is predicted. MethOds: 
The proposed approach ensures that the starting age-specific event rate multiplied 
by the cumulative effect of increasing age during the time horizon of the risk func-
tion equals the original risk prediction. To illustrate and compare the standard and 
the proposed approach, 10-year risk is modelled and compared to the initial 10-year 
predicted risk using the latest Framingham risk function for primary cardiovascular 
(CVD) event risk (D’Agostino et al. 2008). Scenarios are investigated using different 
starting age and different initial predicted risk level. Results: The standard risk 
annualization approach consistently overestimates the modelled risk over a 10-year 
horizon compared with the initial risk prediction for the same period. To illustrate, 
for a 50-year old male with initial 10-year CVD risk of 20%, 30% or 40% the corre-
sponding modelled risk is 25%, 37% and 49%, respectively. The proposed method for 
risk annualization provides the exact 10-year initial risk. cOnclusiOns: Careful 
application of approach for time period adjustment of existing risk functions for use 
in state-transition models is needed when age is included as a risk factor and the 
model cycle length differs from the time horizon of the risk function. The standard 
risk annualization approach will lead to an overestimation of modelled risk and a 
more favorable estimate of cost-effectiveness.
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Time to perform 7 clearly pre-specified tasks was recorded by trained observers 
using a stopwatch. Time of day measurements for subject time in GP surgery and 
vaccination room as well as consumables usage was collected. Time for tasks before 
vaccination day was obtained from opinion. A total 123 processes were observed 
(approximately 20 by site, equally distributed across visits 1 to 4). Analyses were 
run by site and pooled across sites using a random intercept model. Published 
2014 PSSRU data were used to transfer HCP time into cost. Results: Mean HCP 
time for a vaccination process (including a mean 2.75 vaccine doses) was 9.5min 
(95% CI: 7.7-11.3); site range: 7.0-11.3min. Associated cost (90% practice nurse, 10% 
support staff) was £6.2; range: £4.7-£7.7. Mean time for a single oral and intramus-
cular vaccine administration was 1.0 and 0.4min, respectively. Mean time for a 
single vaccine reconstitution was 0.8min. Mean time in GP surgery was 23.9min 
(95% CI: 19.2-28.5), of which 8.4min in vaccination room (95% CI: 5.5-11.2). When 
including average supplies cost (£0.27), as well as an estimated 10.1 minutes per 
vaccination process prior to vaccination day (£5.5), total estimated cost per visit 
was £12.0. cOnclusiOns: Paediatric vaccination requires substantial resources, 
including staff, facility, and parental time. Potential changes in the vaccination 
schedule would have an impact on associated time and cost and the vaccination 
unit’s capacity to managing subjects.
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1National Clinical Guideline Centre, Royal College of Physicians (on behalf of the guideline 
development group), London, UK, 2King’s College London, London, UK, 3Newcastle upon Tyne 
Hospitals NHS Trust, Newcastle, UK
Objectives: To assess the clinical and cost-effectiveness of basal insulin regimens 
for adults with type 1 diabetes mellitus (T1DM), from the English National Health 
Service (NHS) perspective, and inform NICE recommendation regarding optimal 
choice of basal insulin. MethOds: We considered seven daily insulin regimens: 
neutral protamine hagedorn (NPH) (once (od), twice (bid) and four-times daily 
(qid)), detemir (od and bid), glargine (od) and degludec (od). A systematic review of 
randomised controlled trials (RCTs) published in Medline, Embase and Cochrane 
databases to August 2014 was undertaken. Relative effectiveness was assessed 
using Bayesian network meta-analysis (NMA) undertaken in WinBUGs. Two out-
comes were analysed: change in haemoglobin A1c (HbA1c) and rate of severe/major 
hypoglycaemia. The cost-utility analysis (CUA) was undertaken using the IMS-CORE 
Diabetes Model (IMS-CDM), following NICE reference case (lifetime time horizon, 
3.5% discount rate for both costs and QALYs (quality-adjusted life-years), net 
monetary benefit (NMB) calculated using a threshold of £20,000 per QALY gained). 
Sensitivity analyses were performed; including changing insulin dose, discount rate 
and cost of hypoglycaemic events. Results: Twenty eight RCTs were included in 
the NMA. The mean change in HbA1c ranged from -0.48% (SE= 0.10) for detemir-(bid) 
to –0.01% (SE= 0.17) for NPH-(qid). Mean rate of severe/major hypoglycaemia ranged 
from 29 (95%CI: 0.00 to 39.76) to 35 (95%CI: 0.00 to 46.73) events/100 person-years. 
The CUA showed that detemir-(bid) had the highest mean QALY-gain (11.09) and 
NMB (£181,456) per patient. Insulin glargine-(od) ranked second. Insulin degludec-
(od) was the most costly, with the highest treatment cost (£7,169). The optimal 
choice was robust to all changes except when high doses of detemir-(bid) were 
assumed (> 30% increment compared to other regimens); where glargine-(od) ranked 
first. cOnclusiOns: Insulin detemir administered twice daily was the optimal 
basal regimen for adults with T1DM from the English NHS perspective; providing 
the highest QALY gain and NMB among the regimens considered.
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Objectives: The annual incidence of venous thromboembolic (VTE) disease in 
Europe is 183 per 100,000. If preventative measures are not taken one in three surgi-
cal patients can experience a VTE. This study estimated the cost-effectiveness of 
novel oral anticoagulants in two primary prevention populations; post hip (THR) 
and post knee (TKR) replacement surgery. MethOds: For both TKR and THR popula-
tions, initial consequences (180 days) were modelled using a decision tree, followed 
by a Markov model for long term consequences. We evaluated cost-effectiveness of 
dabigatran, rivaroxaban and apixaban, compared with low molecular weight heparin 
(LMWH). Subjects that experienced a recurrent event were treated with apixaban 
and then received aspirin daily for the remainder of their lives. Model inputs dif-
fered between the two populations. Relative treatment efficacy and safety inputs 
came from network meta-analyses; other model inputs were based on a variety of 
evidence sources. Discounted (3.5%) health and benefits (QALYs) over a lifetime were 
estimated. Results: In the THR population rivaroxaban had the highest incremental 
net monetary benefit of £453 (£-485 to £1,312) versus LMWH at a willingness to pay at 
£20,000 per QALY. Dabigatran and apixaban had a negative incremental net monetary 
benefit; £-1,066 (£-12,127 to £3,191) and £-2,284 (£-11,017 to £2,085) respectively. The 
results of the TKR population followed a similar trend. Rivaroxaban had the highest 
were assumed to be $5 (Minimum-Maximum for Scenario Analysis [Min-Max SA]: 
2-10) and $1, respectively. Both costs and benefits were discounted at 3%. Results: 
Over 42 malaria endemic sub-Saharan countries, vaccination with RTS,S at DTP-
coverage was estimated to avert 7.8 (95%CI:4.2-10.6) and 9.3 (95%CI:4.9-12.7) million 
malaria episodes and 50,198 (95%CI:-7,759-108,565) and 63,114 (95%CI:12,218-
110,465) malaria deaths for a birth cohort vaccinated without and with a 4th dose, 
respectively. The overall incremental cost-effectiveness ratio was estimated to reach 
$232 (Min-Max SA:111-433) and $248 (Min-Max SA:119-462) per disability-adjusted 
life-years averted without and with 4th dose, respectively. cOnclusiOns: The 
potential public health impact of implementing RTS,S in infants is estimated to be 
substantial and likely a cost-effective intervention referring to the WHO willingness-
to-pay threshold. However impact and cost-effectiveness of RTS,S would increase if 
malaria vaccination is given at a later age when a higher efficacy has been reported.
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Objectives: Trivalent influenza vaccine (TIV) contains two Influenza A strains, 
but only one of the two B-lineages, resulting in frequent mismatches between vac-
cines and circulating B-lineages during seasonal epidemics. Quadrivalent influ-
enza vaccine (QIV) prevents such mismatches by including both B-lineages. The 
objective of our study was to estimate the cost-effectiveness (CE) of QIV versus TIV 
in Germany by coupling influenza incidence generated by a dynamic individual-
based simulation to health and economic outcomes. MethOds: An individual-
based simulation tool (known in the literature as 4FLU) was refined to estimate 
the impact of TIV and QIV on clinical infection incidence per year and age over 20 
calendar years in Germany. Cases were subsequently linked to health and economic 
outcomes. Inputs were gathered from national databases and published literature. 
Vaccination rates reflect the current coverage in Germany; 2014 was used as the 
baseline year for costs. The productivity costs (societal perspective) were calculated 
according to the human capital approach. Costs and effects were discounted at 
3% and 1.5%, respectively. Univariate and probabilistic sensitivity analyses were 
performed. Results: Per 100,000 inhabitants, QIV prevents 6,803 more clinical 
influenza cases and 6.45 more deaths than TIV, accumulated in 20 years. From the 
societal perspective, QIV dominates TIV, with € 1,424,323 of cost savings and 152 
QALYs gained (98 QALYs by preventing clinical cases and 54 QALYs by avoiding 
premature mortality). These results are sensitive to changes in perspective, vacci-
nation coverage, vaccine prices, productivity cost approach and discount rates, yet 
favorable CE remains. cOnclusiOns: Based on our analysis, QIV is expected to be 
cost-effective, or even cost-saving in Germany. Our results are in line with findings 
from other studies using dynamic models and for other settings.
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Objectives: Vaccination is established as one of the most effective methods to 
prevent influenza and reduce the related social and economic burden. The objec-
tives of this study were to estimate the cost-effectiveness ratios of using the live 
attenuated influenza vaccine (LAIV), indicated for children aged 2 to 18 years, 
as well as evaluate the impact of herd immunity in the non-vaccinated popula-
tion. MethOds: An adaptable and flexible dynamic transmission model, stratified 
by age, was used to simulate the impact of influenza infection, with a time horizon 
of 5 years. This study was conducted in a payer perspective and was adapted to 
the Portuguese setting, as all data related to demographics and costs belonged to 
Portuguese sources. Results: In the base case scenario, two different childhood 
vaccination policies were compared: use the trivalent influenza vaccine (TIV) cur-
rently in the market or use the LAIV, both for healthy children population. For 
the same number of vaccinated individuals, the LAIV achieved a reduction in the 
incidence of influenza and in the number of deaths due to influenza mostly among 
the elderly, when compared with the results obtained with TIV. The incremental 
cost-effectiveness ratios obtained were 7,448 and 8,527€ /QALY, for a vaccination 
coverage of 25 and 75%, respectively. The net monetary benefit obtained was posi-
tive. cOnclusiOns: The results showed that the strategy for influenza vaccination 
using LAIV in children is cost-effective as it reduces the costs related to influenza 
infection and has a positive impact in the Portuguese healthcare from direct and 
indirect protection in the community.
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Objectives: Few studies have estimated time and associated cost related to a pae-
diatric vaccination visit. Time and Motion (T&M) methodology is suitable to collect 
efficiency-related outcomes. The aim was to quantify active healthcare professional 
(HCP) time and associated costs of a single vaccination process administered in a 
paediatric population in the UK. MethOds: Paediatric vaccination processes were 
observed in 6 General Practitioner (GP) surgeries across UK in children 2-14 months. 
